News & Updates

Show Multimedia Only

Distant recurrence rates in early-stage breast cancer decreased in RCTs after the 2000s

26 Nov 2024 by

Women with early-stage breast cancer (BC) entering randomized controlled trials (RCTs) after the 2000s have reduced rates of distant recurrence vs the 1990s, a patient-level pooled analysis by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) has shown.

Distant recurrence rates in early-stage breast cancer decreased in RCTs after the 2000s

26 Nov 2024

Olverembatinib shows therapeutic potential in chronic-phase CML

23 Nov 2024

The novel, small-molecule, orally administered third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) olverembatinib is well-tolerated and shows promising antitumour activity in patients with heavily pretreated chronic-phase chronic myeloid leukaemia (CML), according to the results of a phase 1B study.

Olverembatinib shows therapeutic potential in chronic-phase CML

23 Nov 2024

Is ChatGPT ready to give CRC screening recommendations?

20 Nov 2024 by

The performance of ChatGPT in determining appropriate colorectal cancer (CRC) screening recommendations is relatively poor, with inconsistent responses in several questions, reports a study.

Is ChatGPT ready to give CRC screening recommendations?

20 Nov 2024

Complete response and long-term survival possible with locoregional therapy plus IO in patients with unresectable HCC

20 Nov 2024 by

A cohort study conducted by researchers from the University of Hong Kong (HKU) reports a complete response (CR) rate of 46.0 percent among patients with locally advanced, unresectable hepatocellular carcinoma (HCC) who were treated with locoregional therapy (LRT) plus immunotherapy (IO) and a 3-year overall survival (OS) rate of 75.5 percent among patients with CR.

Complete response and long-term survival possible with locoregional therapy plus IO in patients with unresectable HCC

20 Nov 2024

Induction chemo plus CRT improves PFS and OS vs CRT alone in locally advanced cervical cancer

20 Nov 2024 by

The international, multicentre, randomized phase III GCIG INTERLACE trial reports significantly higher 5-year progression-free survival (PFS) and overall survival (OS) rates with induction chemotherapy followed by chemoradiotherapy (CRT) vs CRT alone in patients with locally advanced cervical cancer.

Induction chemo plus CRT improves PFS and OS vs CRT alone in locally advanced cervical cancer

20 Nov 2024

3L EGFR-MET bispecific antibody in a patient with EGFR ex20ins–positive NSCLC after haemorrhagic stroke

19 Nov 2024 by

This was a 60-year-old woman with a history of diabetes and end-stage kidney disease (ESKD) requiring haemodialysis three times a week. She was admitted to the hospital in June 2022 due to shortness of breath and chest tightness lasting for 1 month. Her Eastern Cooperative Oncology Group performance status (ECOG PS) was 2.

3L EGFR-MET bispecific antibody in a patient with EGFR ex20ins–positive NSCLC after haemorrhagic stroke

19 Nov 2024

Dr Elena Elez of Vall d’Hebron University Hospital shares CRC case treated with BEACON regimen

19 Nov 2024

Dr Elena Elez of Vall d’Hebron University Hospital, Barcelona, Spain, shares a case of an elderly patient with colorectal cancer (CRC) treated with the BEACON regimen (encorafenib plus cetuximab).

Dr Elena Elez of Vall d’Hebron University Hospital shares CRC case treated with BEACON regimen

19 Nov 2024

Prof Julien Taieb treats BRAFV600E-mutant mCRC with encorafenib + cetuximab

19 Nov 2024

Professor Julien Taieb of Georges Pompidou European Hospital in Paris, France, shares a case of a 58-year-old female diagnosed with BRAF^V600E-mutant colorectal cancer, whose disease progressed and became metastatic following FOLFOX. Subsequent treatment with pembrolizumab was not tolerated well and the patient was switched to encorafenib plus cetuximab, which led to improvement in patient’s general condition and allowed cytoreductive surgery followed by complete tumour regression.

Prof Julien Taieb treats BRAFV600E-mutant mCRC with encorafenib + cetuximab

19 Nov 2024

Expanding role of SSAs in neuroendocrine tumour management

19 Nov 2024 by

High-dose somatostatin analogues (SSAs) can be effective and well-tolerated second-line therapies in neuroendocrine tumours (NETs) progressing on standard-dose SSAs in selected cases, according to Dr Ingrid Mak of the University of Hong Kong, at the 7th Endocrinology, Diabetes & Metabolism Hong Kong Annual Meeting (EDM HK 2024).

Expanding role of SSAs in neuroendocrine tumour management

19 Nov 2024

Trastuzumab deruxtecan improves PFS in metastatic breast cancer, but ups ILD risk

18 Nov 2024

Treatment with trastuzumab deruxtecan (T-DXd) demonstrates efficacy in patients with metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) breast cancer but may result in adverse events, such as interstitial lung disease (ILD), suggests a study.

Trastuzumab deruxtecan improves PFS in metastatic breast cancer, but ups ILD risk

18 Nov 2024

News & Updates

Filter by Specialty:

Specialty:

Distant recurrence rates in early-stage breast cancer decreased in RCTs after the 2000s

Distant recurrence rates in early-stage breast cancer decreased in RCTs after the 2000s

Olverembatinib shows therapeutic potential in chronic-phase CML

Olverembatinib shows therapeutic potential in chronic-phase CML

Is ChatGPT ready to give CRC screening recommendations?

Is ChatGPT ready to give CRC screening recommendations?

Complete response and long-term survival possible with locoregional therapy plus IO in patients with unresectable HCC

Complete response and long-term survival possible with locoregional therapy plus IO in patients with unresectable HCC

Induction chemo plus CRT improves PFS and OS vs CRT alone in locally advanced cervical cancer

Induction chemo plus CRT improves PFS and OS vs CRT alone in locally advanced cervical cancer

3L EGFR-MET bispecific antibody in a patient with EGFR ex20ins–positive NSCLC after haemorrhagic stroke

3L EGFR-MET bispecific antibody in a patient with EGFR ex20ins–positive NSCLC after haemorrhagic stroke

Dr Elena Elez of Vall d’Hebron University Hospital shares CRC case treated with BEACON regimen

Dr Elena Elez of Vall d’Hebron University Hospital shares CRC case treated with BEACON regimen

Prof Julien Taieb treats BRAFV600E-mutant mCRC with encorafenib + cetuximab

Prof Julien Taieb treats BRAFV600E-mutant mCRC with encorafenib + cetuximab

Expanding role of SSAs in neuroendocrine tumour management

Expanding role of SSAs in neuroendocrine tumour management

Trastuzumab deruxtecan improves PFS in metastatic breast cancer, but ups ILD risk

Trastuzumab deruxtecan improves PFS in metastatic breast cancer, but ups ILD risk